Ferric Citrate Reduces Intravenous Iron and Erythropoiesis-Stimulating Agent Use in ESRD

• Published in: Journal of the American Society of Nephrology Vol. 26; no. 10; pp. 2578 - 2587
• Main Authors: Umanath, Kausik, Jalal, Diana I., Greco, Barbara A., Umeukeje, Ebele M., Reisin, Efrain, Manley, John, Zeig, Steven, Negoi, Dana G., Hiremath, Anand N., Blumenthal, Samuel S., Sika, Mohammed, Niecestro, Robert, Koury, Mark J., Ma, Khe-Ni, Greene, Tom, Lewis, Julia B., Dwyer, Jamie P.
• Format: Journal Article
• Language: English
• Published: United States American Society of Nephrology 01.10.2015
• Subjects: Administration, Intravenous; Anemia - drug therapy; Anemia - etiology; Clinical Research; Drug Therapy, Combination; Female; Ferric Compounds - therapeutic use; Hematinics - administration & dosage; Humans; Iron - administration & dosage; Kidney Failure, Chronic - complications; Male; Middle Aged; ESRD; dialysis; ESA; iron; phosphate binder; ferric citrate; anemia; erythropoietin

Ferric citrate (FC) is a phosphate binder with shown efficacy and additional effects on iron stores and use of intravenous (iv) iron and erythropoiesis-stimulating agents (ESAs). We provide detailed analyses of changes in iron/hematologic parameters and iv iron/ESA use at time points throughout the...